Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 311 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Graft vs Host Disease Clear all
Completed Phase 3 Interventional Results available

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

NCT01471444
View directory record Official record
Conditions
Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection
Interventions
Fludarabine, Clofarabine, Busulfan, Thymoglobulin, Stem Cell Infusion, Tacrolimus, Methotrexate
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 70 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 14, 2026, 4:54 AM EDT
Terminated Phase 2 Interventional Results available

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

NCT02991898
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Large-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Hodgkin Lymphoma, Multiple Myeloma, Acute Myelogenous Leukemia, Biphenotypic Leukemia, Undifferentiated Leukemia
Interventions
Infusion of Treg
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 4 Interventional

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

NCT00003398
View directory record Official record
Conditions
Anemia, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, thiotepa, allogeneic bone marrow transplantation, bone marrow ablation with stem cell support, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Up to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

NCT01231412
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Plasma Cell Myeloma, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hodgkin Lymphoma, Small Lymphocytic Lymphoma, T-Cell Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Sirolimus, Total-Body Irradiation
Procedure · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
6
States / cities
Denver, Colorado • Atlanta, Georgia • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 14, 2026, 4:54 AM EDT
Completed No phase listed Observational

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease

NCT01521039
View directory record Official record
Conditions
Acute Graft-versus-Host Disease, Allogeneic Stem Cell Transplant
Interventions
Blood samples
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

University of Wisconsin hMSC Cell Bank: Bone Marrow Donor Protocol

NCT01463475
View directory record Official record
Conditions
Graft Versus Host Disease (GVHD), Acute Myocardial Infarction (AMI)
Interventions
Bone marrow aspirate
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 35 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 14, 2026, 4:54 AM EDT
Completed No phase listed Observational

Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation

NCT00528853
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease

NCT00726375
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
Etanercept (Enbrel)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 14, 2026, 4:54 AM EDT
Withdrawn Phase 3 Interventional

Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT

NCT03066466
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
Interventions
Atorvastatin, Methotrexate, Tacrolimus
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

NCT03613727
View directory record Official record
Conditions
Lymphoid Leukemia, Myeloid Leukemia, Monocytic Leukemia, Myelodysplasia
Interventions
Intravenous (IV) and oral Vitamin C
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 77 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2Phase 3 Interventional

Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease

NCT00035880
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
ABX-CBL
Drug
Lead sponsor
Abgenix
Industry
Eligibility
1 Year and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 4:54 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

NCT02619617
View directory record Official record
Conditions
Cluster Headache - Episodic and Chronic
Interventions
SOM230, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Culver City, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)

NCT02806947
View directory record Official record
Conditions
Acute GVHD
Interventions
Sirolimus, Prednisone
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
21
States / cities
Duarte, California • Los Angeles, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02683525
View directory record Official record
Conditions
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Interventions
Sitagliptin
Drug
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 1 Interventional

Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)

NCT00967096
View directory record Official record
Conditions
Malignancy, Bone Marrow Transplantation
Interventions
Rifaximin
Drug
Lead sponsor
Emory University
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Not applicable Interventional

Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia

NCT00001623
View directory record Official record
Conditions
Graft vs Host Disease, Hematologic Neoplasm, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Allogeneic Bone Marrow Transplant
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 14, 2026, 4:54 AM EDT
Completed No phase listed Observational Results available

Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease

NCT02194439
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

NCT02652130
View directory record Official record
Conditions
Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease, Grade D Acute Graft Versus Host Disease
Interventions
Remestemcel-L
Biological
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
2 Months to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 14, 2026, 4:54 AM EDT
Terminated Phase 2 Interventional

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00005641
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

NCT02953678
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Prednisone or methylprednisolone
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant

NCT01244906
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation
Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 14, 2026, 4:54 AM EDT
Terminated Phase 2Phase 3 Interventional

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

NCT03805789
View directory record Official record
Conditions
Acute-graft-versus-host Disease
Interventions
AAT, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

NCT01295710
View directory record Official record
Conditions
GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome
Interventions
US-ATG-F, Placebo
Biological
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 14, 2026, 4:54 AM EDT
Terminated Phase 3 Interventional

Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease

NCT00282503
View directory record Official record
Conditions
Acute Graft-versus-Host Disease
Interventions
Methoxsalen+ECP, Methylprednisolone, Ecp
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Gainesville, Florida • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 14, 2026, 4:54 AM EDT